ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will present at two upcoming investor events:
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company's common stock (...
GeoVax Labs NASDAQ: GOVX is currently a micro-cap biotech stock that multiple Wall Street analysts see massive potential appreciation in. Working on a treatment for a disease that the World Health Organization (WHO) just declared a “public health emergency," investors should be informed about the company.
GeoVax Labs Inc.'s stock GOVX, +1.27% tumbled 20% in premarket trade Tuesday, after the clinical-stage biotech said it's entered an agreement with an institutional investor for the purchase and sale of 1.7 million shares priced at $5 each in a registered direct offering. The stock closed Monday up 1.7% at $7.15, after a rollercoaster session that saw it soar more than 40% at its peak, on excite...
ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,700,000 shares of the Company's common stock...
MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.
GeoVax Labs Inc.'s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet its main goal.
Company to Discuss Recent Mpox Developments as Well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.